AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
Jan 5, 2024
OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that shareholders have elected all four of the Company's directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William M. Mitchell, at the Company's 2023...
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
Dec 29, 2023
Court Finds Activist Group "Flouted" AIM's Bylaws by Failing to Provide Required Information AIM Will Reconvene Annual Meeting Today and then Adjourn Until January 5th Any Proxies Submitted by Activist Group Will Be Disregarded AIM Urges Shareholders to Vote on the...
AIM ImmunoTech Provides Update Regarding Annual Meeting
Nov 28, 2023
AIM Will Convene Annual Meeting on December 1st and then Adjourn Until December 29th to Give Delaware Court Additional Time to Deliver Ruling in Activist Group Litigation OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Nov 27, 2023
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today...
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Nov 21, 2023
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the last subject has completed treatment in the Company's Phase 2 study...
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
Nov 15, 2023
- Highlights continued execution across Ampligen® clinical development programs - Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 - Will host conference call and webcast today, November 15th at 8:30 AM ET...
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
Nov 14, 2023
Data published in The Journal for ImmunoTherapy of CancerOCALA, Fla., Nov. 14, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in...
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
Nov 9, 2023
OCALA, Fla., Nov. 09, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q3 2023 operational and financial results on Wednesday, November 15, 2023...
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
Nov 8, 2023
Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors Phase 2 study...
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
Nov 6, 2023
Highlights AIM's Significant Momentum and Ongoing Achievement of Clinical and Regulatory Milestones Urges Shareholders to Protect AIM's Progress by Voting for the Company's Board of Directors and Discarding Any Proxy Materials from the Activist Group Launches...